

CHAPTER 60 — REFERENCES

- Havenga K, Enker WE, McDermott K, et al. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. *J Am Coll Surg* 1996;182:495–502.
- Havenga K, DeRuiter MC, Enker WE, et al. Anatomical basis of autonomic nerve-preserving total mesorectal excision for rectal cancer. *Br J Surg* 1996;83:384–388.
- Mancini R, Cosimelli M, Filippini A, et al. Nerve-sparing surgery in rectal cancer: feasibility and functional results. *J Exp Clin Cancer Res* 2000;19:35–40.
- McNamara DA, Parc R. Methods and results of sphincter-preserving surgery for rectal cancer. *Cancer Control* 2003;10:212–218.
- Wibe A, Eriksen MT, Syse A, et al. Total mesorectal excision for rectal cancer—what can be achieved by a national audit? *Colorectal Dis* 2003;5:471–477.
- Hanna NN, Guillem J, Dosoretz A, et al. Intraoperative parasympathetic nerve stimulation with tumescence monitoring during total mesorectal excision for rectal cancer. *J Am Coll Surg* 2002;195:506–512.
- Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. *N Engl J Med* 2001;344:1196–1206.
- Compton CC. Surgical pathology of colorectal cancer. In Saltz LB, ed. *Colorectal Cancer: Multimodality Management*. Totowa, NJ: Humana Press; 2002:247–265.
- Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* 2000;124:979–994.
- Topova L, Hellmich G, Puffer E, et al. Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. *Dis Colon Rectum* 2011;54:401–411.
- de Campos-Lobato LF, Stochhi L, da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. *Ann Surg Oncol* 2011;18:1590–1598.
- Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *Br J Surg* 2012;99:918–928.
- Jang NY, Kang SB, Kim DW, et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. *Dis Colon Rectum* 2011;54:245–252.
- Kim CW, Yu CS, Yang SS, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. *Ann Surg Oncol* 2011;18:3271–3277.
- Song S, Hong JC, McDonnell SE, et al. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. *Ann Surg Oncol* 2012;19:2471–2476.
- Ayez N, Alberda WJ, Burger JW, et al. Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary? *Ann Surg Oncol* 2013;20:155–160.
- Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. *Int J Radiat Oncol Biol Phys* 2002;54:386–396.
- Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. *J Clin Oncol* 2004;22:1778–1784.
- Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. *J Clin Oncol* 2001;19:157–163.
- Goldstein NS, Sanford W, Coffey M, et al. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. *Am J Clin Pathol* 1996;106:209–216.
- Wong JH, Severino R, Honnabier MB, et al. Number of nodes examined and staging accuracy in colorectal carcinoma. *J Clin Oncol* 1999;17:2896–2900.
- Doll D, Gertler R, Maak M, et al. Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance. *World J Surg* 2009;33:340–347.
- Rullier A, Laurent C, Capdepon M, et al. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. *Am J Surg Pathol* 2008;32:45–50.
- Wang H, Safar B, Wexner S, et al. Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply? *Dis Colon Rectum* 2009;52:549–557.
- de Campos-Lobato LF, Stocchi L, de Sousa JB, et al. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! *Ann Surg Oncol* 2013;20:3398–3406.
- Klos CL, Bordeianou LG, Sylla P, et al. The prognostic value of lymph node ratio after neoadjuvant chemoradiation and rectal cancer surgery. *Dis Colon Rectum* 2011;54:171–175.
- Kobayashi H, Mochizuki H, Kato T, et al. Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study. *Int J Colorectal Dis* 2011;26:891–896.
- Kang J, Hur H, Min BS, et al. Prognostic impact of the lymph node ratio in rectal cancer patients who underwent preoperative chemoradiation. *J Surg Oncol* 2011;104:53–58.
- Quirke P, Durley P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. *Lancet* 1986;2:996–999.
- Adam JJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. *Lancet* 1994;344:707–711.
- Kim NK, Kim MJ, Yun SH, et al. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. *Dis Colon Rectum* 1999;42:770–775.
- Beynon J. An evaluation of the role of rectal endosonography in rectal cancer. *Ann R Coll Surg Engl* 1989;71:131–139.
- Garcia-Aguilar J, Pollack J, Lee SH, et al. Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. *Dis Colon Rectum* 2002;45:10–15.
- MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. *BMJ* 2006;333:779.
- Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. *Radiology* 2003;227:371–377.
- Brown G, Richards CJ, Newcombe RG, et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. *Radiology* 1999;211:215–222.
- Shihab OC, Taylor F, Salerno G, et al. MRI predictive factors for long-term outcomes of low rectal tumours. *Ann Surg Oncol* 2011;18:3278–3284.
- Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *J Clin Oncol* 2011;29:3753–3760.
- Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. *Ann Surg* 2011;253:711–719.
- Shihab OC, How P, West N, et al. Can a novel MRI staging system for low rectal cancer aid surgical planning? *Dis Colon Rectum* 2011;54:1260–1264.
- Hunter CJ, Garant A, Vuong T, et al. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment. *Ann Surg Oncol* 2012;19:1199–1205.
- National Comprehensive Cancer Network Guidelines for Rectal Cancer, Version 3.2011. [www.nccn.org](http://www.nccn.org).
- Haider MA, Amitai MM, Rappaport DC, et al. Multi-detector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better? *Radiology* 2002;225:137–142.
- Semelka RC, Schlund JF, Molina PL, et al. Malignant liver lesions: comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. *J Magn Reson Imaging* 1996;6:39–43.
- Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. *J Nucl Med* 2000;41:1177–1189.
- Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. *Radiology* 1998;206:755–760.
- Cipe G, Ergul N, Hasbahceci M, et al. Routine use of positron-emission tomography/computed tomography for staging of primary colorectal cancer: does it affect clinical management? *World J Surg Oncol* 2013;11:49.
- Canter RJ, Williams NN. Surgical treatment of colon and rectal cancer. *Hematol Oncol Clin North Am* 2002;16:907–926.
- Saraste D, Gunnarsson U, Janson M. Predicting lymph node metastases in early rectal cancer. *Eur J Cancer* 2013;49:1104–1108.
- Wu ZY, Zhao G, Chen Z, et al. Oncological outcomes of transanal local excision for high risk T(1) rectal cancers. *World J Gastrointest Oncol* 2012;4:84–88.
- Greenberg JA, Shibata D, Herndon JE 2nd, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. *Dis Colon Rectum* 2008;51:1185–1191, discussion 1191–1194.
- Ota DM, Nelson H, ACOSOG Group Co-Chairs. Local excision of rectal cancer revisited: ACOSOG protocol Z6041. *Ann Surg Oncol* 2007;14:271.
- Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann Surg Oncol* 2012;19:384–391.
- Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. *Br J Surg* 2012;99:1211–1218.
- Sgourakis G, Lanitis S, Gockel I, et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. *Am Surg* 2011;77:761–772.

56. Wu Y, Wu YY, Li S, et al. TEM and conventional rectal surgery for T1 rectal cancer: a meta-analysis. *Hepatogastroenterology* 2011;58:364–368.
57. Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135 patients with small nonadvanced low rectal cancer (iT1–iT2, iN0): short- and long-term results. *Surg Endosc* 2011;25:1222–1229.
58. Ramirez JM, Aquilella V, Valencia J, et al. Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results. *Int J Colorectal Dis* 2011;26:437–443.
59. Allaix ME, Rebecchi F, Giaccone C, et al. Long-term functional results and quality of life after transanal endoscopic microsurgery. *Br J Surg* 2011;98:1635–1643.
60. Ganai S, Kanumuri P, Rao RS, et al. Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. *Ann Surg Oncol* 2006;13:547–556.
61. Herzog U, von Flue M, Tondelli P, et al. How accurate is endorectal ultrasound in the preoperative staging of rectal cancer? *Dis Colon Rectum* 1993;36:127–134.
62. Libutti SK, Forde KA. Surgical considerations III: bowel anastomosis. In: Cohen A, Weaver S, eds. *Cancer of the Colon, Rectum and Anus*. New York, NY: McGraw Hill; 1995:445–456.
63. Ota DM, Jacobs L, Kuvshinov B. Rectal cancer: the sphincter-sparing approach. *Surg Clin North Am* 2002;82:983–993.
64. Moore HG, Riedel E, Minsky BD, et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. *Ann Surg Oncol* 2003;10:80–85.
65. Fitzgerald TL, Brinkley J, Zervos EE. Pushing the envelope beyond a centimeter in rectal cancer: oncologic implications of close, but negative margins. *J Am Coll Surg* 2011;213:589–595.
66. Kuvshinov B, Maghfoor I, Miedema B, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? *Ann Surg Oncol* 2001;8:163–169.
67. Pahlman L, Bujko K, Rutkowski A, et al. Altering the therapeutic paradigm towards a distal bowel margin of < 1 cm in patients with low-lying rectal cancer: a systematic review and commentary. *Colorectal Dis* 2013;15:e166–e174.
68. Tiret E, Poupardin B, McNamara D, et al. Ultralow anterior resection with intersphincteric dissection—what is the limit of safe sphincter preservation? *Colorectal Dis* 2003;5:454–457.
69. Martin ST, Heneghan HM, Winter DC. Systematic review of outcomes after intersphincteric resection for low rectal cancer. *Br J Surg* 2012;99:603–612.
70. Denost Q, Laurent C, Capdepon M, et al. Risk factors for fecal incontinence after intersphincteric resection for rectal cancer. *Dis Colon Rectum* 2011;54:963–968.
71. Barisic G, Markovic V, Popovic M, et al. Function after intersphincteric resection for low rectal cancer and its influence on quality of life. *Colorectal Dis* 2011;13:638–643.
72. Nathanson DR, Espat NJ, Nash GM, et al. Evaluation of preoperative and postoperative radiotherapy on long-term functional results of straight colonic anastomosis. *Dis Colon Rectum* 2003;46:888–894.
73. Sitzler PJ, Seow-Choen F, Ho YH, et al. Lymph node involvement and tumor depth in rectal cancers: an analysis of 805 patients. *Dis Colon Rectum* 1997;40:1472–1476.
74. Willett CG. Sphincter preservation in rectal cancer. *Curr Treat Options Oncol* 2000;1:399–405.
75. Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. *J Am Coll Surg* 1995;181:335–346.
76. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* 2001;345:638–646.
77. Tocchi A, Mazzoni G, Lepre L, et al. Total mesorectal excision and low rectal anastomosis for the treatment of rectal cancer and prevention of pelvic recurrences. *Arch Surg* 2001;136:216–220.
78. Zhou ZC, Wang Z, Yu YY, et al. Laparoscopic total mesorectal excision of low rectal cancer with preservation of anal sphincter: a report of 82 cases. *World J Gastroenterol* 2003;9:1477–1481.
79. Tsang WW, Chung CC, Li MK. Prospective evaluation of laparoscopic total mesorectal excision with colonic J-pouch reconstruction for mid and low rectal cancers. *Br J Surg* 2003;90:867–871.
80. Morino M, Parini U, Giraudo G, et al. Laparoscopic total mesorectal excision: a consecutive series of 100 patients. *Ann Surg* 2003;237:335–342.
81. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 2005;365:1718–1726.
82. Cheung HY, Ng KH, Leung AL, et al. Laparoscopic sphincter-preserving total mesorectal excision: 10-year report. *Colorectal Dis* 2011;13:627–631.
83. Lam HD, Stefano M, Tran-Ba T, et al. Laparoscopic versus open techniques in rectal cancer surgery: a retrospective analysis of 121 sphincter-saving procedures in a single institution. *Surg Endosc* 2011;25:454–462.
84. Sartori CA, Dal Pazzo A, Franzato B, et al. Laparoscopic total mesorectal excision for rectal cancer: experience of a single center with a series of 174 patients. *Surg Endosc* 2011;25:508–514.
85. Cone MM, Lu KC, Herzig DO, et al. Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up. *Surg Endosc* 2011;25:1902–1906.
86. Li S, Chi P, Lin H, et al. Long-term outcomes of laparoscopic surgery versus open resection for middle and lower rectal cancer: an NTICLES study. *Surg Endosc* 2011;25:3175–3182.
87. Greenblatt DY, Rajamanickam V, Pugely AJ, et al. Short-term outcomes after laparoscopic-assisted proctectomy for rectal cancer: results from the ACS NSQIP. *J Am Coll Surg* 2011;212:844–854.
88. Liang X, Hou S, Liu H, et al. Effectiveness and safety of laparoscopic resection versus open surgery in patients with rectal cancer: a randomized, controlled trial from China. *J Laparoendosc Adv Surg Tech A* 2011;21:381–385.
89. Huang MJ, Liang JL, Wang H, et al. Laparoscopic-assisted versus open surgery for rectal cancer: a meta-analysis of randomized controlled trials on oncologic adequacy of resection and long-term oncologic outcomes. *Int J Colorectal Dis* 2011;26:415–421.
90. Ohtani H, Tamamori Y, Azuma T, et al. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and conventional open surgery for rectal cancer. *J Gastrointest Surg* 2011;15:1375–1385.
91. Ng SS, Lee JF, Yiu RY, et al. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. *Ann Surg* 2014;259:139–147.
92. Lujan J, Valero G, Biondo S, et al. Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. *Surg Endosc* 2013;27:295–302.
93. Westerholm J, Garcia-Osogobio S, Farrokhyr F, et al. Midterm outcomes of laparoscopic surgery for rectal cancer. *Surg Innov* 2012;19:81–88.
94. Soop M, Nelson H. Laparoscopic-assisted proctectomy for rectal cancer: on trial. *Ann Surg Oncol* 2008;15:2357–2359.
95. deSouza AL, Prasad LM, Marecik SJ, et al. Total mesorectal excision for rectal cancer: the potential advantage of robotic assistance. *Dis Colon Rectum* 2010;53:1611–1617.
96. Koh DC, Tsang CB, Kim SH. A new application of the four-arm standard da Vinci(R) surgical system: totally robotic-assisted left-sided colon or rectal resection. *Surg Endosc* 2011;25:1945–1952.
97. Leong QM, Son DN, Cho JS, et al. Robot-assisted intersphincteric resection for low rectal cancer: technique and short-term outcome for 29 consecutive patients. *Surg Endosc* 2011;25:2987–2992.
98. Bertani E, Chiappa A, Biffi R, et al. Assessing appropriateness for elective colorectal cancer surgery: clinical, oncological, and quality-of-life short-term outcomes employing different treatment approaches. *Int J Colorectal Dis* 2011;26:1317–1327.
99. Baek JH, Pastor C, Pigazzi A. Robotic and laparoscopic total mesorectal excision for rectal cancer: a case-matched study. *Surg Endosc* 2011;25:521–525.
100. Kwak JM, Kim SH, Kim J, et al. Robotic vs laparoscopic resection of rectal cancer: short-term outcomes of a case-control study. *Dis Colon Rectum* 2011;54:151–156.
101. Biffi R, Luca F, Pozzi S, et al. Operative blood loss and use of blood products after full robotic and conventional low anterior resection with total mesorectal excision for treatment of rectal cancer. *J Robot Surg* 2011;5:101–107.
102. Yang Y, Wang F, Zhang P, et al. Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. *Ann Surg Oncol* 2012;19:3727–3736.
103. Trastulli S, Farinella E, Cirocchi R, et al. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. *Colorectal Dis* 2012;14:e134–e156.
104. Memon S, Heriot AG, Murphy DG, et al. Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. *Ann Surg Oncol* 2012;19:2095–2101.
105. Scarpinata R, Aly EH. Does robotic rectal cancer surgery offer improved early postoperative outcomes? *Dis Colon Rectum* 2013;56:253–262.
106. Collinson FJ, Jayne DG, Pigazzi A, et al. An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. *Int J Colorectal Dis* 2012;27:233–241.
107. Mukherjee A. Total pelvic exenteration for advanced rectal cancer. *SD J Med* 1999;52:153–156.
108. Mohan HM, Evans MD, Larkin JO, et al. Multivisceral resection in colorectal cancer: a systematic review. *Ann Surg Oncol* 2013;20:2929–2936.
109. Pereira P, Ghouti L, Blanche J. Surgical treatment of extraluminal pelvic recurrence from rectal cancer: oncological management and resection techniques. *J Visc Surg* 2013;150:97–107.
110. Chew MH, Brown WE, Masya L, et al. Clinical, MRI, and PET-CT criteria used by surgeons to determine suitability for pelvic exenteration surgery for recurrent rectal cancers: a Delphi study. *Dis Colon Rectum* 2013;56:717–725.
111. Ripley RT, Gajdos C, Reppert AE, et al. Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: thermo-surgical ablation. *J Surg Oncol* 2013;107:144–147.
112. Puseddu C, Sotgia B, Melis L, et al. Painful pelvic recurrence of rectal cancer: percutaneous radiofrequency ablation treatment. *Abdom Imaging* 2013;38:1225–1233.
113. Monzon L, Wasan H, Leen E, et al. Transrectal high-intensity focused ultrasonography is feasible as a new therapeutic option for advanced recurrent rectal cancer: report on the first case worldwide. *Ann R Coll Surg Engl* 2011;93:e119–121.

114. Mendenhall MW, Million RR, Pfaff PW. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 1983;9:877–985.
115. Walz B, Lindstrom ER, Butcher HR Jr, et al. Natural history of patients after abdominal-perineal resection implications for radiation therapy. *Cancer* 1977;39:2437–2442.
116. Pilipshen SJ, Heilweil M, Quan SH, et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. *Cancer* 1984;53:1354–1362.
117. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum. *Cancer* 1974;34:1278–1292.
118. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. *Cancer* 1990;66:49–55.
119. Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. *Cancer* 1983;52:1317–1329.
120. Martling A, Holm T, Johansson H, et al. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. *Cancer* 2001;92:896–902.
121. Heald RJ. The “Holy Plane” of rectal surgery. *J Royal Soc Med* 1988;81:503–508.
122. Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. *Arch Surg* 1998;133:894–899.
123. Arbmán G, Nilsson E, Hallböök O, et al. Local recurrence following total mesorectal excision for rectal cancer. *Br J Surg* 1996;83:375–379.
124. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011;12:575–582.
125. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet* 2009;373:811–820.
126. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. *N Engl J Med* 1997;336:980–987.
127. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. *N Engl J Med* 1985;312:1465–1472.
128. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. *N Engl J Med* 1991;324:709–715.
129. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. *J Natl Cancer Inst* 1988;80:21–29.
130. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. *J Natl Cancer Inst* 2000;92:388–396.
131. Balslev IB, Pedersen M, Teglbjaerg PS, et al. Postoperative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. *Cancer* 1986;58:22–28.
132. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. *Lancet* 1996;348:1610–1614.
133. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med* 1994;331:502–507.
134. Schrag D, Weiser M, Goodman K, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol* 2014;32:513–518.
135. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. *Lancet* 2001;358:1291–1304.
136. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. *JAMA* 2000;284:1008–1015.
137. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731–1740.
138. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 2012;30:1926–1933.
139. Wolff HA, Conradi LC, Beissbarth T, et al. Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. *Radiother Oncol* 2013;108:48–54.
140. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. *J Clin Oncol* 2009;27:5124–5130.
141. Hyams D, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. *Dis Colon Rectum* 1997;40:131–139.
142. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg* 2006;93:1215–1223.
143. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol* 2012;30:3827–3833.
144. Pettersson D, Holm T, Iversen H, et al. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. *Br J Surg* 2012;99:577–583.
145. Pach R, Kulig J, Richter P, et al. Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5-year follow-up. *Langenbecks Arch Surg* 2012;397:801–807.
146. Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. *Br J Surg* 2013;100:933–939.
147. Loos M, Quentmeier P, Schuster T, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol* 2013;20:1816–1828.
148. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med* 2006;355:1114–1123.
149. McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. *Cochrane Database Syst Rev* 2012;12:CD008368.
150. De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. *Cochrane Database Syst Rev* 2013;2:CD006041.
151. Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? *Dis Colon Rectum* 1999;42:167–173.
152. Hernanz F, Revuelta S, Redondo C, et al. Colorectal adenocarcinoma: quality of the assessment of lymph node metastases. *Dis Colon Rectum* 1994;37:373–377.
153. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. *J Clin Oncol* 2001;19:3895–3902.
154. Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the Country of Stockholm. *Lancet* 2000;356:93–96.
155. Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. *BMC Cancer* 2011;11:64.
156. Qiu HZ, Wu B, Xiao Y, et al. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. *Colorectal Dis* 2011;13:1353–1360.
157. Nishioka M, Shimada M, Kurita N, et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. *Cancer Genomics Proteomics* 2011;8:87–92.
158. Guedj N, Bretagnol F, Rautou PE, et al. Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. *Hum Pathol* 2011;42:1702–1709.
159. Griminger PP, Danenberg P, Dellas K, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. *Clin Cancer Res* 2011;17:3469–3477.
160. Yasuda K, Nirei T, Sunami E, et al. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. *Radiat Oncol* 2011;6:49.
161. Moureau-Zabotto L, Farnault B, de Chaisemartin C, et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 2011;80:483–491.
162. Edden Y, Wexner SD, Berho M. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. *Colorectal Dis* 2012;14:555–561.
163. Casado E, Garcia VM, Sanchez JJ, et al. A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. *Clin Cancer Res* 2011;17:4145–4154.
164. Shin US, Yu CS, Kim JH, et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. *Ann Surg Oncol* 2011;18:2232–2239.
165. Chen Z, Liu Z, Li W, et al. Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. *Genes Chromosomes Cancer* 2011;50:689–699.
166. Duldulao MP, Lee W, Nelson RA, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. *Ann Surg Oncol* 2013;20:2166–2171.
167. Clancy C, Burke JP, Coffey JC. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. *Surg Oncol* 2013;22:105–111.
168. Suzuki T, Sadahiro S, Tanaka A, et al. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer. *Int J Radiat Oncol Biol Phys* 2013;85:1232–1238.
169. Govindarajan A, Reidy D, Weiser MR, et al. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. *Ann Surg Oncol* 2011;18:3666–3672.
170. Kiran RP, Kirat HT, Burgess AN, et al. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy? *Ann Surg Oncol* 2012;19:1206–1212.

171. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg* 2004;240:711–717, discussion 717–718.
172. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. *J Clin Oncol* 2011;29:4633–4640.
173. Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. *Ann Surg* 2012;256:965–972.
174. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging–defined poor-risk rectal cancer. *J Clin Oncol* 2006;24:668–674.
175. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxiplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging–defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. *J Clin Oncol* 2010;28:859–865.
176. Cercek A, Goodman KA, Hajj C, et al. Chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. *J Natl Compr Canc Netw* 2014;12:513–519.
177. Perez K, Pricolo V, Vrees M, et al. A phase II study of complete neoadjuvant therapy in rectal cancer (CONTRE): The Brown University Oncology Group. *ASCO Meeting Abstracts* 2013;31:Abstr 335.
178. Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. *Dis Colon Rectum* 2010;53:1692–1698.
179. Smith FM, Chang KH, Sheahan K, et al. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. *Br J Surg* 2012;99:993–1001.
180. Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. *Ann Surg* 2013;258:289–295.
181. Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). *Cancer* 2012;118:3501–3511.
182. Intven M, Reerink O, Philippens ME. Diffusion-weighted MRI in locally advanced rectal cancer: pathological response prediction after neo-adjuvant radiochemotherapy. *Strahlenther Onkol* 2013;189:117–122.
183. Perez RO, Habr-Gama A, Pereira GV, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? *Colorectal Dis* 2012;14:714–720.
184. Duldulao MP, Lee W, Streja L, et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. *Dis Colon Rectum* 2013;56:142–149.
185. Hayden DM, Jakate S, Pinzon MC, et al. Tumor scatter after neoadjuvant therapy for rectal cancer: are we dealing with an invisible margin? *Dis Colon Rectum* 2012;55:1206–1212.
186. Tranchart H, Lefevre JH, Syrczek M, et al. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? *Ann Surg Oncol* 2013;20:1551–1559.
187. Park IJ, You YN, Skibber JM, et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. *Dis Colon Rectum* 2013;56:135–141.
188. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Final report of INT 0114-Adjuvant therapy in rectal cancer: analysis by treatment, stage and gender. *Proceedings of the American Society of Clinical Oncology* 2001;20:123a.
189. Smalley S. Intergroup 0144–Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. *Proceedings of the American Society of Clinical Oncology* 2003;22:251.
190. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. *J Clin Oncol* 2011;29:Abstr 3503.
191. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol* 2012;13:579–588.
192. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. *Ann Oncol* 2012;23:1190–1197.
193. Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. *J Clin Oncol* 2006;24:2557–2562.
194. Rodel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. *J Clin Oncol* 2007;25:110–117.
195. Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. *J Clin Oncol* 2008;26:Abstr 4021.
196. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol* 2014;32:1927–1934.
197. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol* 2010;28:1638–1644.
198. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. *J Clin Oncol* 2012;30:4558–4565.
199. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial. *J Clin Oncol* 2009;27:Abstr CRA4008.
200. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol* 2012;13:679–687.
201. Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. *Oncology (Williston Park)* 2000;14:56–59.
202. Kalofonos HP, Bamias A, Koutas A, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. *Eur J Cancer* 2008;44:1693–1700.
203. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2006;354:567–578.
204. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nat Med* 2004;10:145–147.
205. Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. *Int J Radiat Oncol Biol Phys* 2011;81:677–683.
206. Pinto C, Di Fabio F, Maiello E, et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). *Ann Oncol* 2011;22:2424–2430.
207. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *J Clin Oncol* 2012;30:1620–1627.
208. Spigel DR, Bendell JC, McCleod M, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. *Clin Colorectal Cancer* 2012;11:45–52.
209. Nogue M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging–defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. *Oncologist* 2011;16:614–620.
210. Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. *Radiat Oncol* 2011;6:105.
211. Saltz L, Raben D, Minsky BD, et al. Rectal cancer: presentation with metastatic and locally advanced disease. American College of Radiology. ACR Appropriateness Criteria. *Radiology* 2000;215:1491–1499.
212. Minsky B, Cohen AM, Kemeny N, et al. Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. *Int J Radiat Oncol Biol Phys* 1993;25:821–827.
213. Dosoretz DE, Gunderson LL, Hedberg S, et al. Preoperative irradiation for unresectable rectal and rectosigmoid carcinomas. *Cancer* 1983;52:814–818.
214. Emami B, Pilepich M, Willett C, et al. Effect of preoperative irradiation on resectability of colorectal carcinomas. *Int J Radiat Oncol Biol Phys* 1982;8:1295–1299.
215. Marsh R, Chu NM, Vauthey JN, et al. Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. *Cancer* 1996;78:215–225.
216. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. *J Clin Oncol* 2008;26:3687–3694.
217. Gunderson LL, Nelson H, Martenson JA, et al. Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. *Int J Radiat Oncol Biol Phys* 1997;37:601–614.
218. Nakfoor BM, Willett CG, Shellito PC, et al. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. *Ann Surg* 1998;228:194–200.

219. Tepper JE, Wood WC, Cohen AM. Treatment of locally advanced rectal cancer with external beam radiation, surgical resection, and intraoperative radiation therapy. *Int J Radiat Oncol Biol Phys* 1989;16:1437–1444.
220. Harrison LB, Minsky BD, Enker WE, et al. High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer. *Int J Radiat Oncol Biol Phys* 1998;42:325–330.
221. Wang C, Schulz M. The role of radiation therapy in the management of carcinoma of the sigmoid, rectosigmoid and rectum. *Radiology* 1962;79:1–5.
222. Overgaard M, Overgaard J. Dose-response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. *Radiation Oncol* 1984;1:217–225.
223. Brierley JD, Cummings BJ, Wong CS, et al. Adenocarcinoma of the rectum treated by radical external radiation therapy. *Int J Radiat Oncol Biol Phys* 1995;31:255–259.
224. Frykholm GJ, Isacson U, Nygard K, et al. Preoperative radiotherapy in rectal carcinoma—aspects of acute adverse effects and radiation technique. *Int J Radiat Oncol Biol Phys* 1996;35:1039–1048.
225. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. *Dis Colon Rectum* 1993;36:564–572.
226. Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer. *Dis Colon and Rectum* 1999;42:403–418.
227. Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel and reduction of acute and late effects associated with pelvic irradiation. *Int J Radiat Oncol Biol Phys* 1986;12:1565–1573.
228. Bonadeo FA, Vaccaro CA, Benati ML, et al. Rectal cancer: local recurrence after surgery without radiotherapy. *Dis Colon Rectum* 2001;44:374–379.